SMH
·general
·4 hours ago
Everlab rejects peptide sales, prioritizing safety amid growing customer base
Everlab, a Melbourne health startup, has rejected the sale of peptides, citing safety concerns, despite receiving about 10 inquiries daily. The company, which now has over 20,000 members and raised $65 million, aims to make preventative health accessible to ordinary Australians. With an increasing customer base shifting towards older demographics, Everlab is rebranding beyond its luxury origins.
Summary by OZbrief · SMH
Next
Loving doing this? 🎉
Take it further — get the full app and never miss a moment of what's happening in Australia.
Breaking news alerts
Instant lock-screen notifications the moment big stories break across Australia.
Australian news & events
Politics, sport, weather, local events — all in one swipeable feed, updated around the clock.
Stay ahead of the news cycle
30-second summaries so you're always informed, even on your busiest days.
Loading article…
This publisher's site can't be shown here due to their security settings.
Open full article →No source link available for this article.
✨
Ask AI